Korro Bio, Inc.
KRRO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001703647
In the last 90 days, Korro Bio, Inc. insiders filed 1 open-market purchase and 8 sales; 106 institutions reported holding it in 13F filings for Q2 2026, worth $190.1M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Korro Bio, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 91
- −23 vs. Q1 2021
- Shares held
- 19.6M
- +13.8K (+0.1%) vs. Q1 2021
- Total value
- $193.9M
- +$9.15M (+5.0%) vs. Q1 2021
- New holders
- 12
- 42 more added
- Sold out
- 35
- 26 more reduced
1 institution that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KRRO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 106 | $190.1M |
| Q1 2026 | 99 | $144.8M |
| Q4 2025 | 83 | $60.6M |
| Q3 2025 | 92 | $465.5M |
| Q2 2025 | 71 | $114.8M |
| Q1 2025 | 75 | $169.0M |
| Q4 2024 | 84 | $359.6M |
| Q3 2024 | 71 | $285.3M |
| Q2 2024 | 64 | $285.7M |
| Q1 2024 | 49 | $618.6M |
| Q4 2023 | 40 | $301.5M |
| Q3 2023 | 42 | $2.58M |
| Q2 2023 | 41 | $1.67M |
| Q1 2023 | 43 | $2.52M |
| Q4 2022 | 50 | $28.3M |
| Q3 2022 | 55 | $14.1M |
| Q2 2022 | 58 | $13.0M |
| Q1 2022 | 86 | $33.1M |
| Q4 2021 | 84 | $90.2M |
| Q3 2021 | 88 | $130.4M |
| Q2 2021 | 91 | $193.9M |
| Q1 2021 | 115 | $186.6M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Korro Bio, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Kennedy Capital Management, Inc. | 0 | $0 | 0.00% | −47,953−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −44,197−100.0% | Sold out |
| State of Wisconsin Investment Board | 0 | $0 | 0.00% | −33,800−100.0% | Sold out |
| Cresset Asset Management, LLC | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| EMC Capital Management | 0 | $0 | 0.00% | −29,992−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −20,316−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −20,001−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −18,356−100.0% | Sold out |
| STRS Ohio | 0 | $0 | 0.00% | −17,800−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −10,286−100.0% | Sold out |
| Cerity Partners LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| DLD Asset Management, LP | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −5,551−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −3,769−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −3,500−100.0% | Sold out |
| Bank Julius Baer & Co. Ltd, Zurich | 0 | $0 | 0.00% | −3,158−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −2,861−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −1,446−100.0% | Sold out |
| Benjamin F. Edwards & Company, Inc. | 0 | $0 | 0.00% | −867−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Pacifica Partners Inc. | 0 | $0 | 0.00% | −210−100.0% | Sold out |
| Geneos Wealth Management Inc. | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Panagora Asset Management Inc | 0 | $0 | 0.00% | −33−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −34−100.0% | Sold out |
| Amundi Asset Management US, Inc. | – | – | – | – | Not filed |